Skip to content
Screener

NovoCure NVCR Operating Cash Flow

Operating Cash Flow at other companies

Boston Scientific logo
Boston ScientificBSX
$348M-35.7%
Medtronic logo
MedtronicMDT
$2.57B+1.8%
Nuvation Bio logo
Nuvation BioNUVB
-$42.97M+10.8%
Iovance Biotherapeutics, Inc. logo
Iovance Biotherapeutics, Inc.IOVA
-$60.84M+9.8%
Tango Therapeutics logo
Tango TherapeuticsTNGX
-$44.36M-6.4%
Gyre Therapeutics, Inc. logo
Gyre Therapeutics, Inc.GYRE
-$16.73M-124%

Other financials

Income statement

See full
Revenue$183.6M+15.6%
Gross profit$142.5M+21.4%
Operating income-$10.6M+73.3%
Net income-$15.7M+61.0%
EPS (diluted)-$0.13+63.9%

Balance sheet

See full
Cash & equivalents$93.7M-37.4%
Total debt$37.5M-12.4%
Total equity$338.1M-3.2%
Total assets$795.2M-36.2%

Cash flow

See full
CapEx$6.9M+26.1%
Free cash flow$1.2M+106%

Valuation

See full
Market cap$1.91B+56.6%
Enterprise value$1.85B+66.6%
P/S2.7×+0.8×

Profitability

See full
Gross margin76.1%-0.3pp
Operating margin-22.1%-3.6pp
Net margin-21.2%-3.8pp
FCF margin-3.6%-1.5pp

Returns & leverage

See full
Return on equity-43.2%-4.0pp
Debt / equity0.1×0.0×
Current ratio2.9×+1.4×

Where this comes from

Reported directly by NovoCure in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.

The source filing: NovoCure’s 10-Q, filed July 23, 2026.

Filed
Jul 23, 2026, 6:59 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001645113-26-000062
Line itemThree months ended June 30, 2026Three months ended June 30, 2025Six months ended June 30, 2026Six months ended June 30, 2025Year ended December 31, 2025
Decrease (increase) in other long-term assets2,9071,4124,9493,99010,847
Increase (decrease) in accounts payables and accrued expenses2,7972,107(2,323)(14,313)18,958
Increase (decrease) in other long-term liabilities(2,789)920(5,626)(201)(5,274)
Net cash provided by (used in) operating activities$8,132$(15,936)(5,385)(51,601)(49,031)
Cash flows from investing activities:
Purchase of property, equipment and field equipment$(6,916)$(5,486)(12,068)(16,097)(26,648)
Proceeds from maturity of short-term investments95,000420,000205,000540,0001,285,000
Purchase of short-term investments(94,462)(378,528)(191,563)(494,389)(821,076)

Item 1. Financial Statements

FAQ

What is NovoCure's operating cash flow?
NovoCure (NVCR) reported operating cash flow of $8.13M in Q2 2026.
How has NovoCure's operating cash flow changed year-over-year?
NovoCure's operating cash flow increased by 151.0% year-over-year, from -$15.94M to $8.13M.
What is the long-term trend for NovoCure's operating cash flow?
Over 3 years (2021 to 2025), NovoCure's operating cash flow has grown at a -16.0% compound annual growth rate (CAGR), from $82.76M to -$49.03M.
What does operating cash flow mean?
Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.

Ask your AI about NovoCure's operating cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude